EVs are the body's own delivery format. They cross biological barriers with low immunogenicity, which makes them attractive for repeated dosing — provided loading and isolation can be made reproducible.
How we work on it
Every programme in this area follows the same staged path: target definition, carrier or formulation engineering, validation in physiologically relevant models, then transfer to continuous-flow GMP production. Read the full technology overview or talk to the team.